117 related articles for article (PubMed ID: 27865712)
1. Role for human arylamine N-acetyltransferase 1 in the methionine salvage pathway.
Witham KL; Minchin RF; Butcher NJ
Biochem Pharmacol; 2017 Feb; 125():93-100. PubMed ID: 27865712
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 knockout of human arylamine N-acetyltransferase 1 in MDA-MB-231 breast cancer cells suggests a role in cellular metabolism.
Carlisle SM; Trainor PJ; Hong KU; Doll MA; Hein DW
Sci Rep; 2020 Jun; 10(1):9804. PubMed ID: 32555504
[TBL] [Abstract][Full Text] [Related]
3. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells.
Minchin RF
Biochem J; 1995 Apr; 307 ( Pt 1)(Pt 1):1-3. PubMed ID: 7717963
[TBL] [Abstract][Full Text] [Related]
4. Arylamine N-acetyltransferase 1 protects against reactive oxygen species during glucose starvation: Role in the regulation of p53 stability.
Wang L; Minchin RF; Butcher NJ
PLoS One; 2018; 13(3):e0193560. PubMed ID: 29518119
[TBL] [Abstract][Full Text] [Related]
5. Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.
Stepp MW; Doll MA; Carlisle SM; States JC; Hein DW
Mol Carcinog; 2018 Apr; 57(4):549-558. PubMed ID: 29315819
[TBL] [Abstract][Full Text] [Related]
6. Arylamine N-acetyltransferase I.
Minchin RF; Hanna PE; Dupret JM; Wagner CR; Rodrigues-Lima F; Butcher NJ
Int J Biochem Cell Biol; 2007; 39(11):1999-2005. PubMed ID: 17392017
[TBL] [Abstract][Full Text] [Related]
7. Knockout of human arylamine N-acetyltransferase 1 (NAT1) in MDA-MB-231 breast cancer cells leads to increased reserve capacity, maximum mitochondrial capacity, and glycolytic reserve capacity.
Carlisle SM; Trainor PJ; Doll MA; Stepp MW; Klinge CM; Hein DW
Mol Carcinog; 2018 Nov; 57(11):1458-1466. PubMed ID: 29964355
[TBL] [Abstract][Full Text] [Related]
8. Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines.
Tiang JM; Butcher NJ; Minchin RF
Cancer Med; 2015 Apr; 4(4):565-74. PubMed ID: 25627111
[TBL] [Abstract][Full Text] [Related]
9. Modulation of Human Arylamine
Butcher NJ; Burow R; Minchin RF
Mol Pharmacol; 2020 Aug; 98(2):88-95. PubMed ID: 32487734
[TBL] [Abstract][Full Text] [Related]
10. RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition.
Tiang JM; Butcher NJ; Cullinane C; Humbert PO; Minchin RF
PLoS One; 2011 Feb; 6(2):e17031. PubMed ID: 21347396
[TBL] [Abstract][Full Text] [Related]
11. 5-methyl-tetrahydrofolate and the S-adenosylmethionine cycle in C57BL/6J mouse tissues: gender differences and effects of arylamine N-acetyltransferase-1 deletion.
Witham KL; Butcher NJ; Sugamori KS; Brenneman D; Grant DM; Minchin RF
PLoS One; 2013; 8(10):e77923. PubMed ID: 24205029
[TBL] [Abstract][Full Text] [Related]
12. Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines.
Liu L; Wagner CR; Hanna PE
Chem Res Toxicol; 2009 Dec; 22(12):1962-74. PubMed ID: 19842618
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
Paterson S; Sin KL; Tiang JM; Minchin RF; Butcher NJ
Drug Metab Dispos; 2011 Jan; 39(1):77-82. PubMed ID: 20870783
[TBL] [Abstract][Full Text] [Related]
14. Effect arylamine N-acetyltransferase 1 on morphology, adhesion, migration, and invasion of MDA-MB-231 cells: role of matrix metalloproteinases and integrin αV.
Li P; Butcher NJ; Minchin RF
Cell Adh Migr; 2020 Dec; 14(1):1-11. PubMed ID: 31910058
[TBL] [Abstract][Full Text] [Related]
15. Arylamine N-acetyltransferase 1 in situ N-acetylation on CD3+ peripheral blood mononuclear cells correlate with NATb mRNA and NAT1 haplotype.
Salazar-González RA; Turiján-Espinoza E; Hein DW; Niño-Moreno PC; Romano-Moreno S; Milán-Segovia RC; Portales-Pérez DP
Arch Toxicol; 2018 Feb; 92(2):661-668. PubMed ID: 29043425
[TBL] [Abstract][Full Text] [Related]
16. Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition.
Ragunathan N; Dairou J; Pluvinage B; Martins M; Petit E; Janel N; Dupret JM; Rodrigues-Lima F
Mol Pharmacol; 2008 Jun; 73(6):1761-8. PubMed ID: 18310302
[TBL] [Abstract][Full Text] [Related]
17. Deletion of arylamine N-acetyltransferase 1 in MDA-MB-231 human breast cancer cells reduces primary and secondary tumor growth in vivo with no significant effects on metastasis.
Doll MA; Ray AR; Salazar-González RA; Shah PP; Vega AA; Sears SM; Krueger AM; Hong KU; Beverly LJ; Hein DW
Mol Carcinog; 2022 May; 61(5):481-493. PubMed ID: 35133049
[TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells.
Tiang JM; Butcher NJ; Minchin RF
Biochem Biophys Res Commun; 2010 Feb; 393(1):95-100. PubMed ID: 20100460
[TBL] [Abstract][Full Text] [Related]
19. Placental arylamine N-acetyltransferase type 1: potential contributory source of urinary folate catabolite p-acetamidobenzoylglutamate during pregnancy.
Upton A; Smelt V; Mushtaq A; Aplin R; Johnson N; Mardon H; Sim E
Biochim Biophys Acta; 2000 Dec; 1524(2-3):143-8. PubMed ID: 11113560
[TBL] [Abstract][Full Text] [Related]
20. Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding.
Laurieri N; Kawamura A; Westwood IM; Varney A; Morris E; Russell AJ; Stanley LA; Sim E
BMC Pharmacol Toxicol; 2014 Nov; 15():68. PubMed ID: 25432241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
